NASDAQ$KRYS
Krystal Biotech Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Krystal Biotech reported financial results and operational progress for Q1 2020.
Krystal Biotech reported a net loss of $5.3 million, or $0.31 per share, for the first quarter ended March 31, 2020. The company ended the quarter with $186.7 million in cash, cash equivalents and short-term investments. Krystal Biotech is on track to start the B-VEC Phase 3 pivotal study in the first half of 2020.
- Ended Q1 2020 with $186.7 million in cash, cash equivalents and short-term investments.
- Research and development expenses were $3.5 million for Q1 2020, compared to $3.2 million for Q1 2019.
- General and administrative expenses were $2.4 million for Q1 2020, compared to $1.5 million for Q1 2019.
- Net losses for Q1 2020 were $5.3 million, or ($0.31) per common share, compared to $4.1 million or ($0.29) per common share in Q1 2019.
Headline financials
Revenue & EPS history
Krystal Biotech · Revenue · Quarterly
$116M
Revenue by segment
Krystal Biotech · $91.1M total across 1 segment · Q4 2024
- VYJUVEK Net Product Revenue$91.1M—100.0%
Forward guidance
Krystal Biotech anticipates treating patients across three different clinical trials for skin diseases and conditions and remain committed to developing our pipeline.
Tailwinds
- Manufacturing batch has been cleared for the upcoming B-VEC Phase 3 pivotal study.
- Presently on track to start the pivotal study in the first half of 2020, barring any COVID-19 delays.
- Encouraged by the pre-clinical data to date on KB407, with potential to treat cystic fibrosis.
- Advance Phase 1/2 study to include pediatric patients on KB105 for the treatment of ARCI, following safety review by the FDA.
- Initiate Phase 1 clinical safety and efficacy study on KB301 for an aesthetic indication.
Headwinds
- Uncertainties inherent in the initiation and conduct of clinical trials.
- Availability and timing of data from clinical trials.
- Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals.
- The unanticipated impact of COVID-19 on Krystal’s business operations, pre-clinical activities and clinical trials.
- Sufficiency of cash resources and need for additional financing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+1.3%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+9.5%
Avg return
30 days after
54%
19 / 35 earnings
Positive
+52.8%
Q4 2023
Best reaction
-14.0%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +14.9% | +13.3% | |
| Q4 2025 | +4.0% | -5.3% | -6.7% | |
| Q3 2025 | +4.9% | +0.2% | +10.1% | |
| Q2 2025 | -14.0% | -11.7% | -4.3% | |
| Q1 2025 | -13.8% | -18.6% | -18.3% | |
| Q4 2024 | +12.4% | +19.3% | +19.4% | |
| Q3 2024 | -1.1% | +13.2% | +6.4% | |
| Q2 2024 | -6.9% | -5.1% | -3.1% | |
| Q1 2024 | +0.4% | -3.9% | +4.1% | |
| Q4 2023 | +52.8% | +50.7% | +59.2% | |
| Q3 2023 | -10.7% | -19.3% | -16.1% | |
| Q2 2023 | -6.7% | -4.2% | -0.2% | |
| Q1 2023 | +9.0% | +4.7% | +51.2% | |
| Q4 2022 | +4.4% | +0.7% | +2.0% | |
| Q3 2022 | +7.7% | +4.7% | +1.6% | |
| Q2 2022 | -5.2% | -3.4% | -17.1% | |
| Q1 2022 | -4.7% | +0.4% | +15.4% | |
| Q4 2021 | +2.6% | -8.2% | +7.0% | |
| Q3 2021 | -7.4% | -7.4% | +48.5% | |
| Q2 2021 | -1.6% | -6.2% | -3.2% | |
| Q1 2021 | -7.2% | -4.0% | -7.6% | |
| Q4 2020 | +6.8% | -7.8% | -2.3% | |
| Q3 2020 | +2.6% | +3.1% | +35.0% | |
| Q2 2020 | +0.5% | +6.7% | +11.7% | |
| Q1 2020 | +13.7% | +25.3% | +3.8% | |
| Q4 2019 | -0.7% | -12.0% | -12.0% | |
| Q3 2019 | +1.6% | +0.5% | +43.5% | |
| Q2 2019 | -4.0% | -3.3% | -6.2% | |
| Q1 2019 | +2.6% | +14.6% | +1.1% | |
| Q4 2018 | -4.1% | +1.9% | +55.6% | |
| Q3 2018 | -4.7% | -1.5% | +5.4% | |
| Q2 2018 | +2.7% | +1.5% | +6.1% | |
| Q1 2018 | +0.1% | +0.2% | +23.5% | |
| Q4 2017 | +5.8% | +21.2% | +2.9% | |
| Q3 2017 | +6.0% | +1.9% | +4.1% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro